Guangzhou Wondfo Biotech Co Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more
Guangzhou Wondfo Biotech Co Ltd (300482) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.09 Billion CNY
Based on the latest financial reports, Guangzhou Wondfo Biotech Co Ltd (300482) has total liabilities worth CN¥1.09 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guangzhou Wondfo Biotech Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guangzhou Wondfo Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guangzhou Wondfo Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥136.22 Million |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
USA | $6.15 Billion |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
China | CN¥1.80 Billion |
|
Investors Real Estate Trust
F:WXC1
|
Germany | €1.21 Billion |
|
DINE S.A.B. de C.V
MX:DINEB
|
Mexico | MX$4.38 Billion |
|
Transcat Inc
NASDAQ:TRNS
|
USA | $176.12 Million |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
China | CN¥13.05 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Guangzhou Wondfo Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangzhou Wondfo Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangzhou Wondfo Biotech Co Ltd (2011–2024)
The table below shows the annual total liabilities of Guangzhou Wondfo Biotech Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.50 Billion | +30.01% |
| 2023-12-31 | CN¥1.16 Billion | -34.39% |
| 2022-12-31 | CN¥1.76 Billion | +30.47% |
| 2021-12-31 | CN¥1.35 Billion | +2.99% |
| 2020-12-31 | CN¥1.31 Billion | +171.48% |
| 2019-12-31 | CN¥483.45 Million | -10.47% |
| 2018-12-31 | CN¥540.01 Million | +6.97% |
| 2017-12-31 | CN¥504.82 Million | +234.32% |
| 2016-12-31 | CN¥151.00 Million | +54.19% |
| 2015-12-31 | CN¥97.93 Million | +1.54% |
| 2014-12-31 | CN¥96.44 Million | +1.65% |
| 2013-12-31 | CN¥94.88 Million | -21.01% |
| 2012-12-31 | CN¥120.12 Million | +2.21% |
| 2011-12-31 | CN¥117.52 Million | -- |